Life Quality Study for PFAPA Patient

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This cohort study aims to assess the quality of life (or welfare) related to the health of children and adolescents with an non genetics auto-inflammatory disease PFAPA or Marshall syndrome to compare it to children or adolescents with recurrent fever genetics of Familial Mediterranean fever (FMF) in order to improve their overall care.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03331497` - Tonsillotomy or Follow-up in PFAPA Syndrome	N/A
	Recruiting	`NCT05200715` - AutoInflammatory Disease Alliance Registry (AIDA)

NCT number	NCT02811705
Study type	Observational
Source	Versailles Hospital
Contact
Status	Completed
Phase
Start date	July 2015
Completion date	April 2017

Life Quality Study for PFAPA Patient — PFAPA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms